EVOK Stock Price, Evoke Pharma Inc Quote, Chart

Market Summary

0.470.00

Market Closed

0.00%

EVOK Stock Price

View Fullscreen

EVOK RSI Chart

EVOK Valuation

Market Cap

4.0M

Price/Earnings (Trailing)

-0.57

Price/Sales (Trailing)

0.66

Price/Free Cashflow

-0.68

EVOK Price/Sales (Trailing)

EVOK Profitability

Return on Equity

-203.85%

Return on Assets

-57.24%

Free Cashflow Yield

-146.84%

EVOK Fundamentals

EVOK Revenue

Revenue (TTM)

6.1M

Rev. Growth (Yr)

114.15%

Rev. Growth (Qtr)

3.55%

EVOK Earnings

Earnings (TTM)

-7.1M

Earnings Growth (Yr)

29.57%

Earnings Growth (Qtr)

20.51%

Breaking Down EVOK Revenue

Last 7 days

2.2%

Last 30 days

-14.5%

Last 90 days

-30.9%

Trailing 12 Months

-72.0%

How does EVOK drawdown profile look like?

EVOK Financial Health

Current Ratio

1.39

Debt/Equity

1.05

Debt/Cashflow

-1.61

EVOK Investor Care

Shares Dilution (1Y)

157.17%

Diluted EPS (TTM)

-1.83

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	6.1M	0	0	0
2023	2.9M	3.6M	4.3M	5.2M
2022	1.9M	2.2M	2.1M	2.5M
2021	111.9K	347.4K	1.3M	1.6M
2020	0	0	0	23.0K
2015	7.7K	5.6K	4.3K	0
2014	9.9K	12.3K	13.4K	10.2K
2013	3.1K	4.5K	5.9K	7.2K
2012	0	0	6.2K	1.7K
2011	0	0	0	10.7K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Evoke Pharma Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 14, 2020	gonyer david a	sold	-70,424	2.94	-23,954	president and ceo
Dec 11, 2020	gonyer david a	sold	-139,333	2.9	-48,046	president and ceo
Dec 11, 2020	d'onofrio matthew j	sold	-117,439	2.91	-40,357	exec vp, chief bus. officer
Dec 10, 2020	d'onofrio matthew j	sold	-16,646	2.95	-5,643	exec vp, chief bus. officer
Dec 09, 2020	gonyer david a	acquired	28,800	0.4	72,000	president and ceo
Dec 09, 2020	d'onofrio matthew j	acquired	18,400	0.4	46,000	exec vp, chief bus. officer
Sep 01, 2020	gonyer david a	acquired	21,249	1.05	20,238	president and ceo
Sep 01, 2020	d'onofrio matthew j	acquired	21,249	1.05	20,238	exec vp, chief bus. officer
Sep 01, 2020	carlson marilyn r.	acquired	21,249	1.05	20,238	chief medical officer
Mar 02, 2020	d'onofrio matthew j	acquired	21,250	0.85	25,000	exec vp, chief bus. officer

Which funds bought or sold EVOK recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Tower Research Capital LLC (TRC)	added	14.88	-2,251	4,517	-%
May 15, 2024	Nantahala Capital Management, LLC	new	-	411,750	411,750	0.02%
May 15, 2024	Altium Capital Management LP	new	-	442,215	442,215	0.17%
May 15, 2024	MORGAN STANLEY	unchanged	-	-165	229	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	new	-	8,217	8,217	-%
May 15, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	new	-	6,630	6,630	-%
May 14, 2024	NewEdge Advisors, LLC	unchanged	-	-91.00	127	-%
May 14, 2024	Bleichroeder LP	new	-	503,250	503,250	0.13%
May 14, 2024	AIGH Capital Management LLC	new	-	516,404	516,404	0.16%

Are Funds Buying or Selling EVOK?

Are funds buying EVOK calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own EVOK

No. of Funds

Unveiling Evoke Pharma Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 13, 2024	lytton laurence w	9.99%	859,322	SC 13G
Mar 11, 2024	bleichroeder lp	9.99%	849,367	SC 13G
Feb 20, 2024	altium capital management lp	9.7%	822,986	SC 13G
Feb 13, 2024	hirschman orin	9.99%	847,000	SC 13G
May 06, 2021	hirschman orin	5.3%	1,701,185	SC 13G
Mar 26, 2021	hirschman orin	4.4%	1,433,113	SC 13G/A
Jan 20, 2021	hirschman orin	5.3%	1,700,000	SC 13G
Feb 11, 2020	sphera funds management ltd.	0%	0	SC 13G

Recent SEC filings of Evoke Pharma Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	DEFA14A	DEFA14A
May 14, 2024	10-K/A	Annual Report
May 14, 2024	10-Q	Quarterly Report
May 14, 2024	8-K	Current Report
May 14, 2024	8-K	Current Report
May 14, 2024	ARS/A	ARS/A
Apr 10, 2024	ARS	ARS
Apr 10, 2024	DEF 14A	DEF 14A
Apr 10, 2024	DEFA14A	DEFA14A
Mar 29, 2024	PRE 14A	PRE 14A

Peers (Alternatives to Evoke Pharma Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	372.2B	85.6B	6.82%	-1.69%	9.67	4.35	5.68%	202.39%
MRK	332.3B	61.4B	4.65%	15.09%	144.1	5.41	6.11%	-82.30%
AMGN	167.7B	29.5B	18.35%	39.38%	44.55	5.68	12.76%	-52.47%
PFE	162.3B	57.8B	12.71%	-21.46%	129.52	2.81	76.51%	-86.81%
GILD	84.4B	27.4B	1.23%	-13.37%	174.21	3.07	1.51%	-91.32%
TEVA	18.4B	16.0B	23.52%	97.09%	-37.29	1.15	7.23%	71.10%
MID-CAP
ALKS	4.1B	1.7B	0.67%	-19.91%	9.41	2.37	54.01%	364.56%
PRGO	4.1B	4.6B	-0.70%	-10.77%	-528.11	0.89	-0.06%	94.55%
BHC	2.5B	9.0B	-21.94%	-21.03%	-5.45	0.28	10.01%	-27.45%
AMPH	2.1B	676.2M	8.56%	-0.82%	13.75	3.14	30.38%	66.04%
SMALL-CAP
TLRY	1.5B	743.2M	15.12%	-18.85%	-4.35	2.06	24.65%	80.36%
TXMD	25.8M	1.3M	18.52%	-47.17%	-3.49	19.84	-98.14%	-104.71%
ACRX	18.4M	89.6M	6.93%	25.60%	-1.29	0.19	287.27%	-129.41%
AGRX	2.5M	21.5M	2.70%	-90.89%	-0.32	0.12	66.16%	61.83%
ACOR	633.5K	115.7M	-50.00%	-97.38%	0	0.01	-2.22%	-352.48%

Evoke Pharma Inc News

Latest updates

Evoke Pharma Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2015Q3	2015Q2	2015Q1	2014Q4	2014Q3	2014Q2	2014Q1
Revenue	3.5%	1,735	1,676	1,563	1,131	810	796	832	462	418	361	930	237	90.00	20.00	470*	1.00	2.00	1.00	2.00	3.00	4.00
Operating Expenses	-9.2%	3,237	3,564	3,166	2,916	2,966	2,506	2,745	2,574	2,470	1,908	2,775	2,406	2,681	2,232	-	-	-	-	-	-	-
S&GA Expenses	-9.8%	3,140	3,482	3,131	2,766	2,848	2,289	2,614	2,315	2,405	1,736	2,635	2,142	2,338	2,042	-	-	-	-	-	-	-
R&D Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,088	2,875	1,852
Interest Expenses	-1.1%	125	126	126	125	123	126	126	125	123	126	126	125	123	20.00	78.00	78.00	77.00	7.00	6.00	58.00	37.00
Net Income	20.5%	-1,579	-1,987	-1,693	-1,867	-2,243	-1,803	-2,013	-2,233	-2,173	-1,672	-1,969	-2,290	-2,605	-2,267	-	-	-	-	-	-	-
Net Income Margin	22.4%	-1.17*	-1.50*	-1.77*	-2.22*	-2.86*	-3.28*	-3.90*	-3.71*	-4.17*	-5.28*	-7.15*	-26.75*	-	-	-	-	-	-	-	-	-
Free Cashflow	-133.2%	-2,579	-1,106	-1,041	-1,206	-1,630	-2,506	-1,100	-1,373	-1,615	-1,997	-5,892	-1,510	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	76.2%	12,454	7,069	7,853	8,980	10,039	11,851	13,411	14,404	9,026	10,573	11,650	17,557	19,296	9,434	6,751	8,267	4,638	6,396	7,327	7,631	4,363
Current Assets	82.4%	12,454	6,827	7,840	8,927	9,948	11,722	13,257	14,404	9,026	10,561	11,601	17,472	19,176	9,281	6,715	8,196	4,533	6,246	7,292	7,561	4,260
Cash Equivalents	104.7%	9,703	4,739	6,000	7,006	8,200	9,844	12,350	13,451	7,701	9,145	11,142	16,721	18,186	8,069	6,281	7,990	4,133	5,664	6,505	7,440	4,029
Inventory	22.2%	589	482	505	514	365	289	220	268	279	186	225	234	236	236	86.00	-	-	-	-	-	-
Liabilities	-7.2%	8,957	9,648	8,727	8,441	7,913	7,767	7,878	7,213	7,092	7,018	6,877	11,592	11,485	12,649	8,674	8,641	5,328	2,015	-	-	-
Current Liabilities	195.0%	8,957	3,036	2,240	2,081	1,678	1,655	1,878	1,353	1,357	1,406	1,390	6,231	6,249	7,536	6,621	6,641	1,716	2,015	2,154	1,285	1,287
Shareholder's Equity	235.6%	3,497	-2,579	-873	538	2,100	4,085	5,533	7,191	1,934	3,555	4,773	5,966	7,811	-	-	-	2,922	4,381	5,173	6,346	3,075
Retained Earnings	-1.3%	-125,019	-123,439	-121,452	-119,758	-117,890	-115,647	-113,843	-111,830	-109,596	-107,423	-105,750	-103,781	-101,490	-98,885	-96,617	-94,488	-87,520	-85,730	-84,312	-82,684	-80,570
Additional Paid-In Capital	6.3%	128,516	120,860	120,578	120,296	120,016	119,731	119,376	119,021	111,527	110,978	110,521	109,744	109,299	95,668	94,691	94,112	90,440	90,108	89,483	89,028	83,644
Shares Outstanding	157.2%	8,597	3,343	3,343	3,343	3,343	3,343	3,077	3,157	2,731	2,721	2,712	2,699	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	5,300	-	-	-	10.60*	-	-	-	43,100	-	-	-	88,600	-	-	-	13,200	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-133.2%	-2,579	-1,106	-1,041	-1,206	-1,630	-2,506	-1,100	-1,373	-1,615	-1,997	-5,892	-1,510	-2,953	-1,711	-1,810	-1,556	-1,551	-1,147	-1,059	-1,628	-1,926
Share Based Compensation	-9.8%	254	282	282	280	285	355	356	367	381	454	464	399	561	477	479	363	310	319	331	345	379
Cashflow From Financing	-	7,543	-	-	-	-	-	-	7,123	172	-	313	45.00	13,070	3,500	101	5,413	21.00	307	124	5,040	636

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

EVOK Income Statement

2024-03-31

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net product sales	$ 1,735,490	$ 810,408
Operating expenses:
Cost of goods sold	$ 92,529	$ 50,591
Cost, Product and Service [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember
Research and development	$ 4,645	$ 66,990
Selling, general and administrative	3,139,536	2,847,940
Total operating expenses	3,236,710	2,965,521
Loss from operations	(1,501,220)	(2,155,113)
Other income (expense):
Interest income	46,058	35,331
Interest expense	(124,658)	(123,288)
Total other expense	(78,600)	(87,957)
Net loss	$ (1,579,820)	$ (2,243,070)
Net loss per share of common stock, basic	$ (0.17)	$ (0.67)
Net loss per share of common stock, diluted	$ (0.17)	$ (0.67)
Weighted-average shares used to compute basic net loss per share	9,082,139	3,343,070
Weighted-average shares used to compute diluted net loss per share	9,082,139	3,343,070

EVOK Balance Sheet

2024-03-31

Condensed Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 9,702,755	$ 4,739,426
Accounts receivable, net of allowance for credit losses of $0	1,451,904	673,071
Prepaid expenses	704,215	885,040
Inventories	588,776	481,840
Other current assets	6,312	47,532
Total current assets	12,453,962	6,826,909
Deferred offering costs		241,637
Total assets	12,453,962	7,068,546
Current Liabilities:
Accounts payable and accrued expenses	1,953,959	1,711,778
Accrued compensation	265,881	1,324,010
Note payable	5,000,000	5,000,000
Accrued interest payable	1,736,953	1,612,295
Total current liabilities	8,956,793	9,648,083
Total liabilities	8,956,793	9,648,083
Commitments and contingencies (Note 3)
Stockholders' equity (deficit):
Preferred stock, $0.0001 par value; authorized shares - 5,000,000 as of March 31, 2024 and December 31, 2023; issued and outstanding shares - zero as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.0001 par value; authorized shares - 50,000,000 as of March 31, 2024 and December 31, 2023; issued and outstanding shares - 8,597,405 and 3,343,070 as of March 31, 2024 and December 31, 2023, respectively	859	334
Additional paid-in capital	128,515,568	120,859,567
Accumulated deficit	(125,019,258)	(123,439,438)
Total stockholders' equity (deficit)	3,497,169	(2,579,537)
Total liabilities and stockholders' equity (deficit)	$ 12,453,962	$ 7,068,546

About Evoke Pharma Inc

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

CEO	Mr. David A. Gonyer R.Ph.
WEBSITE	https://evokepharma.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	4

Evoke Pharma Inc Frequently Asked Questions

What is the ticker symbol for Evoke Pharma Inc? What does EVOK stand for in stocks?

EVOK is the stock ticker symbol of Evoke Pharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Evoke Pharma Inc (EVOK)?

As of Fri May 17 2024, market cap of Evoke Pharma Inc is 4.04 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EVOK stock?

You can check EVOK's fair value in chart for subscribers.

What is the fair value of EVOK stock?

You can check EVOK's fair value in chart for subscribers. The fair value of Evoke Pharma Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Evoke Pharma Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EVOK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Evoke Pharma Inc a good stock to buy?

The fair value guage provides a quick view whether EVOK is over valued or under valued. Whether Evoke Pharma Inc is cheap or expensive depends on the assumptions which impact Evoke Pharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EVOK.

What is Evoke Pharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, EVOK's PE ratio (Price to Earnings) is -0.57 and Price to Sales (PS) ratio is 0.66. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EVOK PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Evoke Pharma Inc's stock?

In the past 10 years, Evoke Pharma Inc has provided -0.406 (multiply by 100 for percentage) rate of return.